Rapid Weight Loss vs. Toxicity: What Experts Say About the Cause
The European Medicines Agency (EMA) has granted marketing authorization for an oral formulation of semaglutide, providing a non-injectable option for patients managing type 2 diabetes. This oral GLP-1 receptor agonist is designed to regulate blood sugar levels and support weight management by mimicking the glucagon-like peptide-1 hormone, according to official regulatory filings from the European … Read more